ESTRO PT 2018

Relevance

Evidence

Strength of endpoint

Strength of study design

A. Overall survival (OS)

I.

Randomized controlled clinical trials (RCT)

B. Disease-specific survival (DSS)

II. Non-randomized controlled clinical trials (NRCT)

C. i. Carefully assessed quality of life (Qol) ii. Treatment-induced toxicity

III. Case series (CS)

D. Indirect surrogates

IV. Best case series (BCS)

i. Disease-free survival ii. Progression-free survival iii. Tumor response rate iv. Local and locoregional control

http://www.cancer.gov/cancertopics/pdq/levels-evidence-cam/healthprofessional/

Veldeman L. et al. Lancet Oncol. 2008 Apr;9(4):367-75.